KR102617284B1 - 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물 - Google Patents

면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물 Download PDF

Info

Publication number
KR102617284B1
KR102617284B1 KR1020227031578A KR20227031578A KR102617284B1 KR 102617284 B1 KR102617284 B1 KR 102617284B1 KR 1020227031578 A KR1020227031578 A KR 1020227031578A KR 20227031578 A KR20227031578 A KR 20227031578A KR 102617284 B1 KR102617284 B1 KR 102617284B1
Authority
KR
South Korea
Prior art keywords
human
gene segment
gene
unrearranged
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227031578A
Other languages
English (en)
Korean (ko)
Other versions
KR20220130830A (ko
Inventor
앤드류 제이. 머피
린 맥도날드
춘광 궈
존 맥훠터
베라 보로니나
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020237034902A priority Critical patent/KR102933824B1/ko
Publication of KR20220130830A publication Critical patent/KR20220130830A/ko
Application granted granted Critical
Publication of KR102617284B1 publication Critical patent/KR102617284B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
KR1020227031578A 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물 Active KR102617284B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237034902A KR102933824B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862685203P 2018-06-14 2018-06-14
US62/685,203 2018-06-14
US201862702206P 2018-07-23 2018-07-23
US62/702,206 2018-07-23
US201962812580P 2019-03-01 2019-03-01
US62/812,580 2019-03-01
PCT/US2019/037285 WO2019241692A1 (en) 2018-06-14 2019-06-14 Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
KR1020207036226A KR102444180B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036226A Division KR102444180B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034902A Division KR102933824B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물

Publications (2)

Publication Number Publication Date
KR20220130830A KR20220130830A (ko) 2022-09-27
KR102617284B1 true KR102617284B1 (ko) 2023-12-27

Family

ID=67220854

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227031578A Active KR102617284B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
KR1020207036226A Active KR102444180B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
KR1020237034902A Active KR102933824B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207036226A Active KR102444180B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
KR1020237034902A Active KR102933824B1 (ko) 2018-06-14 2019-06-14 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물

Country Status (25)

Country Link
US (2) US20210251202A1 (https=)
EP (3) EP3629720B1 (https=)
JP (5) JP7182647B2 (https=)
KR (3) KR102617284B1 (https=)
CN (2) CN113430207A (https=)
AU (3) AU2019287727B2 (https=)
CA (1) CA3103646C (https=)
CY (1) CY1125121T1 (https=)
DK (2) DK4023059T3 (https=)
ES (2) ES2994581T3 (https=)
FI (1) FI4023059T3 (https=)
HR (2) HRP20220509T8 (https=)
HU (1) HUE069544T2 (https=)
IL (3) IL318469A (https=)
LT (2) LT3629720T (https=)
MX (2) MX391767B (https=)
PL (2) PL4023059T3 (https=)
PT (2) PT4023059T (https=)
RS (2) RS66298B1 (https=)
SG (1) SG11202012084WA (https=)
SI (2) SI3629720T1 (https=)
SM (2) SMT202400501T1 (https=)
TW (2) TWI840372B (https=)
WO (1) WO2019241692A1 (https=)
ZA (1) ZA202007560B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3424947T (lt) 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
TW202430558A (zh) * 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白重鏈長cdr3轉殖基因構築體及其用途
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
DE69424134T2 (de) 1993-12-03 2000-09-21 Terumo K.K., Tokio/Tokyo Stereoskopisches Bildanzeigesystem
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US7744893B2 (en) * 2002-06-05 2010-06-29 Baylor College Of Medicine T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
EP2346994B1 (en) 2008-09-30 2022-02-16 Ablexis, LLC Knock-in mice for the production of chimeric antibodies
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
KR102203727B1 (ko) 2010-03-31 2021-01-18 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
US9012717B2 (en) 2010-06-22 2015-04-21 Regeneron Pharmaceuticals, Inc. Human lambda light chain mice
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
BR112014006394A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
RS62023B1 (sr) * 2012-02-01 2021-07-30 Regeneron Pharma Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
IN2014DN08163A (https=) 2012-03-06 2015-05-01 Regeneron Pharma
KR102228296B1 (ko) 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
SG10201700360VA (en) 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2014153674A (ru) 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
PT3597037T (pt) * 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
HRP20231356T1 (hr) 2012-12-14 2024-02-16 Omniab, Inc. Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
EP2840892B1 (en) * 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
WO2014160202A1 (en) 2013-03-13 2014-10-02 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CN105189545A (zh) 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
US9475559B2 (en) 2013-07-03 2016-10-25 Hobie Cat Company Foot operated propulsion system for watercraft
WO2015143406A2 (en) * 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR102276752B1 (ko) * 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
HUE049405T2 (hu) 2014-06-23 2020-09-28 Regeneron Pharma Nukleáz-közvetített DNS-összeállítás
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
US9410301B2 (en) 2014-12-09 2016-08-09 Theophile Bourgeois Patch system and method for oil boom
KR102530821B1 (ko) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
WO2018128691A1 (en) * 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
CN207626880U (zh) 2017-05-19 2018-07-20 厦门汇成峰户外用品有限公司 一种导演椅
EP3476942B1 (en) * 2017-10-27 2022-01-26 Trianni, Inc. Long germline dh genes and long hcdr3 antibodies
DK4140297T3 (da) 2017-12-05 2025-06-23 Regeneron Pharma Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Annu Rev Immunol.,24:541-570(2006.)
EMBO J.,7(11):3413-3422(1988.11.)

Also Published As

Publication number Publication date
SI4023059T1 (sl) 2025-03-31
TW202500752A (zh) 2025-01-01
IL305557B1 (en) 2025-03-01
IL305557A (en) 2023-10-01
IL318469A (en) 2025-03-01
AU2019287727A1 (en) 2021-01-14
PL4023059T3 (pl) 2025-03-10
MX2020013652A (es) 2022-04-21
RS63117B1 (sr) 2022-05-31
ZA202007560B (en) 2022-06-29
JP7182647B2 (ja) 2022-12-02
ES2907067T3 (es) 2022-04-21
BR112020025279A2 (pt) 2021-03-09
EP4023059A1 (en) 2022-07-06
HRP20241705T1 (hr) 2025-02-28
EP3629720A1 (en) 2020-04-08
HUE069544T2 (hu) 2025-03-28
JP7815335B2 (ja) 2026-02-17
IL279311B2 (en) 2024-02-01
DK4023059T3 (da) 2024-12-02
CN113430207A (zh) 2021-09-24
TWI840372B (zh) 2024-05-01
KR102933824B1 (ko) 2026-03-05
WO2019241692A1 (en) 2019-12-19
EP3629720B1 (en) 2022-01-19
EP4464720A2 (en) 2024-11-20
SI3629720T1 (sl) 2022-04-29
SG11202012084WA (en) 2021-01-28
US20210251202A1 (en) 2021-08-19
CY1125121T1 (el) 2024-12-13
MX391767B (es) 2025-03-21
PL3629720T3 (pl) 2022-05-02
IL279311B1 (en) 2023-10-01
IL305557B2 (en) 2025-07-01
AU2019287727B2 (en) 2022-12-01
PT3629720T (pt) 2022-03-08
DK3629720T3 (da) 2022-03-07
HRP20220509T1 (hr) 2022-05-27
FI4023059T3 (fi) 2025-01-30
CN112312766A (zh) 2021-02-02
TW202012424A (zh) 2020-04-01
PT4023059T (pt) 2024-11-27
JP2022079617A (ja) 2022-05-26
SMT202200126T1 (it) 2022-05-12
KR20220130830A (ko) 2022-09-27
EP4464720A3 (en) 2025-02-19
SMT202400501T1 (it) 2025-01-14
AU2025200075A1 (en) 2025-01-30
JP2021528057A (ja) 2021-10-21
CA3103646A1 (en) 2019-12-19
IL279311A (en) 2021-01-31
US20190380316A1 (en) 2019-12-19
CA3103646C (en) 2023-06-27
RS66298B1 (sr) 2025-01-31
MX2022004537A (es) 2022-05-10
AU2022268350B2 (en) 2024-11-07
EP4023059B1 (en) 2024-11-06
ES2994581T3 (en) 2025-01-28
KR102444180B1 (ko) 2022-09-16
LT3629720T (lt) 2022-03-10
AU2022268350A1 (en) 2022-12-15
LT4023059T (lt) 2024-12-27
KR20230147213A (ko) 2023-10-20
KR20210020031A (ko) 2021-02-23
JP2024019660A (ja) 2024-02-09
JP2026016787A (ja) 2026-02-03
JP2024111243A (ja) 2024-08-16
HRP20220509T8 (hr) 2022-07-22

Similar Documents

Publication Publication Date Title
US12433264B2 (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
KR102617284B1 (ko) 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
KR20200093570A (ko) 조작된 면역글로불린 람다 경쇄를 갖는 비-인간 동물 및 그의 용도
US20220330532A1 (en) Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
RU2801802C2 (ru) Животные, отличные от человека, способные к dh-dh-перегруппировке сконструированных генных сегментов, и пути их применения
HK40118853A (en) Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
HK40076920A (en) Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
HK40076920B (en) Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
KR20260046460A (ko) 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
JP2026069737A (ja) 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物
HK40016068B (en) Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
HK40016068A (en) Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220913

Application number text: 1020207036226

Filing date: 20201216

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220913

Comment text: Request for Examination of Application

AMND Amendment
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230125

Patent event code: PE09021S01D

AMND Amendment
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230712

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231012

Application number text: 1020207036226

Filing date: 20201216

PX0701 Decision of registration after re-examination

Patent event date: 20231110

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20231012

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230317

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220927

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220913

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231219

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231220

End annual number: 3

Start annual number: 1

PG1601 Publication of registration